New indications of AstraZeneca (AZN.US) Avestrol® approved in China for maintenance treatment of severe eosinophilic asthma in children

^{The Zhitong Finance App learned that AstraZeneca (AZN.US) announced that its new indications for its first respiratory biologic preparation, Fansuzuo® (English product name: Fasenra ®, generic name: benrelizumab injection), have been officially approved in China for the maintenance treatment of severe eosinophilic asthma (SEA) in children (6 to <12 years).}

This approval is based on the positive results of the global multi-center, open-label TATE phase III clinical trial. This is an open-label phase III clinical study conducted in the US and Japan to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and long-term safety of benrelizumab in SEA children aged 6-11 years.

Since it was first approved, sales of Benrelizumab have maintained steady growth, entering the $1 billion ranking in 2021, and global sales reached US$1,689 billion in 2024, an increase of 8.76% over the previous year. According to the semi-annual report disclosed in '25, sales of the drug reached US$920 million in the first half of the year, an increase of 18% over the previous year.